Palumbo, A. Jr et al. HMGA2, but not HMGA1, is overexpressed in human larynx carcinomas. Histopathology (2017).
 Cao, D., Fan, S. T. & Chung, S. S. Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem. 273, 11429-11435 (1998).
 Cousido-Siah, A., et al. Identification of a novel poly- fluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: Structure determination of both ternary complexes and implications for drug design. Acta Crystallogr. D Biol. Crystallogr. 70, 889-903 (2014).
 Endo, S. et al. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids. Arch. Biochem. Biophys. 487, 1-9 (2009).
 Zhong, L., Shen, H., Huang, C., Jing, H. & Cao, D. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. Toxicol. Appl. Pharmacol. 255, 40-47 (2011).
 Quinn, A. M., Harvey, R. G. & Penning, T. M. Oxidation of PAH trans-dihydrodiols by human aldo-keto reductase AKR1B10. Chem. Res. Toxicol. 21, 2207-2215 (2008).
 Crosas, B. et al. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem. J. 373, 973-979 (2003).
 Chung, Y. T. et al. . Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. Mod. Pathol. 25, 758-766 (2012).
 Heringlake, S. et al. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours. J. Hepatol. 52, 220-227 (2010).
 Fukumoto, S., et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers’ non-small cell lung carcinomas. Clin. Cancer Res. 11, 1776-1785 (2005).
 Ko, H. H. et al. Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma. Head Neck 39, 1327-1332 (2017).
 Jin, J. et al. Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate. Sci. Rep. 6, 22746 (2016).
 Ma, J., et al. AKR1B10 overexpression in breast cancer: associa- tion with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker. Int. J. Cancer 131, E862-E871 (2012).
 Ohashi, T., Idogawa, M., Sasaki, Y., Suzuki, H. & Tokino, T. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis. Mol. Cancer Res. 11, 1554-1563 (2013).
 Woenckhaus, M. et al. Smoking and cancer- related gene expression in bronchial epithelium and non-small-cell lung cancers. J. Pathol. 210, 192-204 (2006).
 Pagliuca G, Martellucci S, Degener AM, Pierangeli A, Greco A, Fusconi M, De Virgilio A, Gallipoli C, de Vincentiis M, Gallo A. Role of Human Papillomavirus in the Pathogenesis of Laryngeal Dysplasia. Otolaryngol Head Neck Surg. 2014; 150: 1018-1023
 Matkowskyj, K. A. et al. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions. Hum. Pathol. 45, 834-843 (2014).
. Shen, Y., Liao, D. F. & Cao, D. AKR1B10 in gastrointestinal diseases. Aging (Albany, NY) 7, 221-222 (2015).
 Yoshitake, H., et al. Aldo-keto reductase family 1, member B10 in uterine carcinomas: A potential risk factor of recurrence after surgical therapy in cervical cancer. Int. J. Gynecol. Cancer 17, 1300-1306 (2007).
 Kang, M. W. et al. AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer. J. Int. Med. Res. 39, 78-85 (2011).
 He, Y. C., et al. Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker. Cancer Biomark. 16, 127-135 (2016).
 Li, L. T., Jiang, G., Chen, Q. & Zheng, J. N. Ki67 is a promising molecular target in the diagnosis of cancer. Mol. Med. Rep. 11, 1566-1572 (2015).
 Gioacchini, F. M. et al. The clinical relevance of Ki-67 expression in laryngeal squamous cell carcinoma. Eur. Arch. Otorhinolaryngol 272, 1569-1576 (2015).
 Izawa, H., Yonemitsu, N., Shin, T. & Sugihara, H. Histopathological analysis of apoptosis, and expression of p53, bcl-2, bax, and Ki-67 in laryngeal squamous cell carcinomas and dysplasia. Auris Nasus Larynx 26, 317-330 (1999).
 Acikalin, M. F. & Oner, U., Tel N, Pasaoglu O, Cakli H, Colak E. Prognostic significance of Ki-67 expression for patients with laryngeal squamous cell carcinoma primarily treated by total laryngectomy. Eur. Arch. Otorhinolaryngol. 261, 376-380. (2009)
 Wei, W. et al. Effects of AKR1B10 gene silence on the growth and gene expression of HCC cell line MHCC97H. Zhonghua Gan Zang Bing Za Zhi 18, 666-671 (2010)
 Schmitz, K. J. et al. AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: A clinicopathological study of 168 cases. Liver Int. 31, 810-816 (2011).
 Xu, J. et al. Mutant p53 promotes cell spreading and migration via ARHGAP44. Sci. China Life Sci. 60, 1019-1029 (2017).
 Wang, D., Yi, Z. & Yang, F. Expression of P53 protein in laryngeal carcinoma and its clinical significance. Zhonghua Er Bi Yan Hou Ke Za Zhi 30, 354-356 (1995).
 Li, Y. & Zhang, J. Expression of mutant p53 in oral squamous cell carcinoma is correlated with the effectiveness of intra-arterial chemotherapy. Oncol. Lett. 10, 2883-2887 (2015).
 Curran, S. & Murray, G. I. Matrix metalloproteinases in tumour invasion and metas- J. Pathol. 189, 300-308 (1999).
 Liu, R. R. et al. Matrix metalloproteinase 2 (MMP2) protein expression and laryngeal cancer prognosis: a meta analysis. Int. J. Clin. Exp. Med. 8, 2261-2266 (2015).
 Li, J., et al. AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling. Oncotarget 8, 33694-33703 (2017).
 Takemura, M. et al. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid. J. Nat. Prod. 74, 1201-1206 (2011).
 Zu, X. et al. Aldo-keto reductase 1B10 protects human colon cells from DNA damage induced by electrophilic carbonyl compounds. Mol. Carcinog. 56, 118-129 (2017).
 Jung, Y. J. et al. AKR1B10-inhibitory Selaginella tamariscina extract and amentoflavone decrease the growth of A549 human lung cancer cells in vitro and in vivo. J. Ethnopharmacol. 202, 78-84 (2017).
 Pillai, K., Pourgholami, M. H., Chua, T. C. & Morris, D. L. Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma. Am. J. Clin. Oncol. 38, 388-394 (2015).
 Kropveld, A., Slootweg, P. J., Blankenstein, M. A., Terhaard, C. H. & Hordijk, G. J. Ki-67 and p53 in T2 laryngeal cancer. Laryngoscope 108, 1548–1552 (1998).